Healthcare provider profile · identity verified

Nicole Ramig Phillips, M.D.

Internal Medicine · INDIANAPOLIS, IN · NPI 1386870772

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	628	174
Amlodipine Besylate	Amlodipine Besylate	363	109
Levothyroxine Sodium	Levothyroxine Sodium	362	90
Omeprazole	Omeprazole	353	101
Losartan Potassium	Losartan Potassium	333	85
Gabapentin	Gabapentin	267	83
Lisinopril	Lisinopril	250	72
Hydrochlorothiazide	Hydrochlorothiazide	209	56
Sertraline Hcl	Sertraline Hcl	203	55
Duloxetine Hcl	Duloxetine Hcl	180	49
Metformin Hcl	Metformin Hcl	165	48
Mounjaro	Tirzepatide	164	27
Metoprolol Succinate	Metoprolol Succinate	160	44
Fluoxetine Hcl	Fluoxetine Hcl	155	38
Alendronate Sodium	Alendronate Sodium	139	37
Trazodone Hcl	Trazodone Hcl	136	40
Fluticasone Propionate	Fluticasone Propionate	131	46
Famotidine	Famotidine	126	39
Bupropion Xl	Bupropion Hcl	122	31
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	117	25
Rosuvastatin Calcium	Rosuvastatin Calcium	116	36
Ozempic	Semaglutide	109	16
Tamsulosin Hcl	Tamsulosin Hcl	108	28
Metoprolol Tartrate	Metoprolol Tartrate	92	27
Simvastatin	Simvastatin	90	27
Pantoprazole Sodium	Pantoprazole Sodium	89	30
Albuterol Sulfate Hfa	Albuterol Sulfate	84	21
Allopurinol	Allopurinol	77	23
Valsartan	Valsartan	77	21
Pravastatin Sodium	Pravastatin Sodium	76	18
Tizanidine Hcl	Tizanidine Hcl	74	28
Eliquis	Apixaban	71	13
Furosemide	Furosemide	69	26
Metformin Hcl Er	Metformin Hcl	62	20
Tramadol Hcl	Tramadol Hcl	61	13
Carvedilol	Carvedilol	56	16
Meloxicam	Meloxicam	56	15
Montelukast Sodium	Montelukast Sodium	52	18
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	46	suppressed
Naproxen	Naproxen	46	18
Clopidogrel	Clopidogrel Bisulfate	44	12
Pioglitazone Hcl	Pioglitazone Hcl	44	13
Potassium Chloride	Potassium Chloride	43	15
Escitalopram Oxalate	Escitalopram Oxalate	42	13
Cephalexin	Cephalexin	41	38
Trulicity	Dulaglutide	41	suppressed
Chlorthalidone	Chlorthalidone	40	11
Glipizide Er	Glipizide	40	11
Azelastine Hcl	Azelastine Hcl	39	17
Synthroid	Levothyroxine Sodium	39	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	37	suppressed
Buspirone Hcl	Buspirone Hcl	36	suppressed
Citalopram Hbr	Citalopram Hydrobromide	36	11
Ezetimibe	Ezetimibe	36	suppressed
Methylprednisolone	Methylprednisolone	36	28
Venlafaxine Hcl Er	Venlafaxine Hcl	36	11
Diclofenac Sodium	Diclofenac Sodium	35	28
Atenolol	Atenolol	34	11
Celecoxib	Celecoxib	34	suppressed
Estradiol	Estradiol	34	15
Dicyclomine Hcl	Dicyclomine Hcl	33	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	30	suppressed
Farxiga	Dapagliflozin Propanediol	29	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	29	suppressed
Ibuprofen	Ibuprofen	29	suppressed
Spironolactone	Spironolactone	29	suppressed
Fluconazole	Fluconazole	27	19
Finasteride	Finasteride	26	suppressed
Januvia	Sitagliptin Phosphate	25	suppressed
Ropinirole Hcl	Ropinirole Hcl	25	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	24	suppressed
Jardiance	Empagliflozin	24	suppressed
Nystatin	Nystatin	24	suppressed
Rybelsus	Semaglutide	24	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	24	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	23	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	23	suppressed
Premarin	Estrogens, Conjugated	22	13
Methocarbamol	Methocarbamol	21	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	21	suppressed
Risedronate Sodium	Risedronate Sodium	21	suppressed
Ondansetron Odt	Ondansetron	20	12
Sumatriptan Succinate	Sumatriptan Succinate	20	suppressed
Topiramate	Topiramate	19	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	18	suppressed
Lidocaine	Lidocaine	18	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	18	suppressed
Amoxicillin	Amoxicillin	17	suppressed
Clonazepam	Clonazepam	17	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Fenofibrate	Fenofibrate	17	suppressed
Propranolol Hcl	Propranolol Hcl	17	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	16
Doxepin Hcl	Doxepin Hcl	16	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Prednisone	Prednisone	16	11
Glimepiride	Glimepiride	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	15	suppressed
Azithromycin	Azithromycin	14	11
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Klayesta	Nystatin	14	suppressed
Klor-Con M20	Potassium Chloride	14	suppressed
Eszopiclone	Eszopiclone	13	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Primidone	Primidone	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Xarelto	Rivaroxaban	13	suppressed
Arnuity Ellipta	Fluticasone Furoate	12	suppressed
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Colchicine	Colchicine	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Naltrexone Hcl	Naltrexone Hcl	12	suppressed
Oxycodone Hcl	Oxycodone Hcl	12	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Irbesartan	Irbesartan	11	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Pen Needle	Pen Needle, Diabetic	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error